Announcement • Apr 09
China SXT Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $0.76 million. China SXT Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $0.76 million.
Security Name: Class A Ordinary Shares
Security Type: Common Stock
Securities Offered: 2,000,000
Price\Range: $0.38
Transaction Features: Registered Direct Offering Announcement • Jan 14
China SXT Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $9.945333 million. China SXT Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $9.945333 million.
Security Name: Class A Ordinary Shares
Security Type: Common Stock
Securities Offered: 12,000,000
Price\Range: $0.15
Discount Per Security: $0.0105
Security Name: Pre-Funded Warrants
Security Type: Equity Warrant
Securities Offered: 54,666,666
Price\Range: $0.149
Discount Per Security: $0.01043
Transaction Features: Registered Direct Offering New Risk • Jan 11
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: US$17.5m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (30% average weekly change). Shareholders have been substantially diluted in the past year (over 266x increase in shares outstanding). Minor Risks Revenue is less than US$5m (US$1.5m revenue). Market cap is less than US$100m (US$17.5m market cap). Announcement • Jan 10
China SXT Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $10 million. China SXT Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.
Security Name: Class A Ordinary Shares
Security Type: Common Stock
Securities Offered: 66,666,666
Price\Range: $0.15
Transaction Features: Registered Direct Offering New Risk • Jan 08
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Shareholders have been substantially diluted in the past year (over 266x increase in shares outstanding). Minor Risk Revenue is less than US$5m (US$1.5m revenue). Reported Earnings • Jan 02
First half 2026 earnings released: US$0.055 loss per share (vs US$0.25 loss in 1H 2025) First half 2026 results: US$0.055 loss per share. Net loss: US$6.37m (loss widened US$5.57m from 1H 2025). Reported Earnings • Aug 01
Full year 2025 earnings released: US$2.32 loss per share (vs US$28.58 loss in FY 2024) Full year 2025 results: US$2.32 loss per share. Revenue: US$1.74m (down 9.7% from FY 2024). Net loss: US$3.30m (loss widened 6.6% from FY 2024). Valuation Update With 7 Day Price Move • May 23
Investor sentiment improves as stock rises 29% After last week's 29% share price gain to US$1.55, the stock trades at a trailing P/E ratio of 4.3x. Average trailing P/E is 17x in the Pharmaceuticals industry in the US. Total loss to shareholders of 100% over the past three years. Valuation Update With 7 Day Price Move • May 07
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to US$1.90, the stock trades at a trailing P/E ratio of 4.5x. Average trailing P/E is 17x in the Pharmaceuticals industry in the US. Total loss to shareholders of 100% over the past three years. Announcement • May 07
China SXT Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $0.1 million. China SXT Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $0.1 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 200,000
Price\Range: $0.5
Transaction Features: Registered Direct Offering Valuation Update With 7 Day Price Move • Apr 15
Investor sentiment deteriorates as stock falls 32% After last week's 32% share price decline to US$1.70, the stock trades at a trailing P/E ratio of 4x. Average trailing P/E is 15x in the Pharmaceuticals industry in the US. Total loss to shareholders of 100% over the past three years. Reported Earnings • Apr 03
First half 2025 earnings released: US$1.99 loss per share (vs US$155 loss in 1H 2024) First half 2025 results: US$1.99 loss per share (improved from US$155 loss in 1H 2024). Net loss: US$802.6k (loss narrowed 92% from 1H 2024). New Risk • Apr 02
New major risk - Revenue and earnings growth Revenue has declined by 2.2% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (46% average weekly change). Revenue has declined by 2.2% over the past year. Shareholders have been substantially diluted in the past year (over 5x increase in shares outstanding). Market cap is less than US$10m (US$1.12m market cap). Minor Risks Latest financial reports are more than 6 months old (reported March 2024 fiscal period end). Revenue is less than US$5m (US$1.9m revenue). Announcement • Mar 18
China SXT Pharmaceuticals Regains Compliance with Nasdaq's Minimum Bid Price Deficiency China SXT Pharmaceuticals, Inc. announced that the Company received a written notification (the “Compliance Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) dated March 13, 2025, informing the Company that it has regained compliance with the Nasdaq Listing Rule 5550(a)(2) (“Minimum Bid Price Requirement”) and the matter is closed. As previously announced, the Company received a notification letter from the Nasdaq dated October 3, 2024, indicating its failure to maintain a minimum bid price of $1.00 per share for 30 consecutive business days under Minimum Bid Price Requirement. Pursuant to the Nasdaq Listing Rules 5810(c)(3)(A), the Company was provided with 180 calendar days, or until April 1, 2025, to regain compliance. To comply with the Minimum Bid Price Requirement, the closing bid price of the Company’s ordinary shares must be at least $1.00 per share for a minimum of 10 consecutive business days at any time prior to April 1, 2025. Therefore, in order to cure the Minimum Bid Price deficiency, the Company has effectuated a share consolidation on February 25, 2025, of which every eight (8) issued and unissued ordinary shares of the Company with no par value each be consolidated into one (1) share with no par value. According to the Compliance Notice, the Company evidenced a closing bid price of its ordinary shares at or greater than $1.00 per share for 10 consecutive business days from February 25, 2025 to March 12, 2025. Thus, the Company has regained compliance with the Minimum Bid Price Requirement, and the matter is closed. New Risk • Mar 02
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (46% average weekly change). Earnings have declined by 18% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 5x increase in shares outstanding). Market cap is less than US$10m (US$1.96m market cap). Minor Risks Latest financial reports are more than 6 months old (reported March 2024 fiscal period end). Revenue is less than US$5m (US$1.9m revenue). New Risk • Feb 24
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 45% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (45% average weekly change). Earnings have declined by 18% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 5x increase in shares outstanding). Market cap is less than US$10m (US$1.19m market cap). Minor Risk Revenue is less than US$5m (US$1.9m revenue). Announcement • Feb 22
China SXT Pharmaceuticals, Inc. Announces Share Consolidation to Regain Compliance with the Minimum Bid Price Requirement China SXT Pharmaceutics, Inc. announced that it will effect a share consolidation of its ordinary shares at a ratio of 1-for-8, effective on February 25, 2025 (the “Share Consolidation”). The Company’s ordinary shares are expected to begin trading on a post-consolidation basis at the open of the market session on February 25, 2025. Upon the market opening on February 25, 2025, the Company’s ordinary shares will continue to be traded on The Nasdaq Stock Market under the symbol “SXTC” with the new CUSIP number G2161P157. The Company’s Board of Directors approved the afore-mentioned Share Consolidation so as to regain compliance with the minimum bid price requirement of $1.00 per share for continued listing on the Nasdaq Stock Market (the “Minimum Bid Price Requirement”). In order to maintain the Company’s listing on the Nasdaq Stock Market, the Company’s ordinary shares must have a closing bid price of $1.00 or more for a minimum of ten consecutive trading days by April 1, 2025. There can be no assurance that following the Share Consolidation, the Company’s ordinary shares will remain above $1.00 per share minimum for the requisite period to regain listing compliance. In the event that the Company does not regain compliance with the Minimum Bid Price Requirement, its securities may be subject to delisting from the Nasdaq Stock Market which, in turn, will result in significant adverse effect on the value and liquidity of the Company’s securities. Announcement • Jan 25
China SXT Pharmaceuticals, Inc. Announces CEO Changes On January 20, 2025, the Board of China SXT Pharmaceuticals, Inc. approved the appointment of Mr. Simon Lim Sze Beng as the Co-Chief Executive Officer (the "Co-CEO") of the Company with immediate effect. In connection with this appointment, the title of Mr. Feng Zhou was changed from the Chief Executive Officer and Director to the Co-CEO and Director of the Company. Mr. Simon Lim Sze Beng is an experienced professional in the healthcare sector. Since 2019, he has served as a manager of Reform Medical Marketing Co., Limited, where he serves clients in medical, and healthcare sectors and promotes their products and services. From 2017 to 2019, he was the senior operations director at Axcel Digital, where he conducts multichannel promotion for healthcare sector clients. He earned a bachelor's degree in arts from Universiti Malaya in Malaysia in 2001. Announcement • Jan 24
China SXT Pharmaceuticals, Inc. Announces Board and Committee Changes On January 20, 2025, Songfan He resigned from his positions as an independent director of the board of directors of China SXT Pharmaceuticals, Inc., the chairman of the audit committee, a member of the compensation committee and nominating & corporate governance committee, effective immediately. Mr. He indicated that his resignation was due to personal reasons and was not the result of any disagreement with management of the Company or the Board. On January 20, 2025, the Board of the Company passed a resolution to appoint Mr. Yong Lip Chee as an independent director of the Board, the chairman of the Audit Committee, a member of the Compensation Committee and the Nominating Committee, to fill in the vacancies result from Mr. He's resignation. Mr. Yong Lip Chee has a background in sales and client relations within the healthcare sector. Since 2021, Mr. Yong has been an independent sales consultant, advising healthcare companies on market penetration strategies and distributor partnerships. From 2017 to 2021, he served as a sales supervisor at Winner Medical Hong Kong, where he promotes medical consumables products to hospitals and private healthcare medical professionals and related users. He earned a bachelor's degree in business administration from Universiti Malaya in Malaysia in 2013. Announcement • Oct 08
China SXT Pharmaceuticals Receives Nasdaq Notification Letter Regarding Bid Price Deficiency China SXT Pharmaceuticals, Inc. announced that on October 3, 2024, the Company received a notification letter from the Nasdaq Listing Qualifications Staff of The NASDAQ Stock Market LLC (“Nasdaq”) notifying the Company that the minimum bid price per share for its ordinary shares has been below $1.00 for a period of 30 consecutive business days and the Company therefore no longer meets the minimum bid price requirements set in Nasdaq Listing Rule 5550(a)(2). The notification received has no immediate effect on the listing of the Company’s ordinary shares on Nasdaq. Under the Nasdaq Listing Rules, the Company has until April 1, 2025, to regain compliance. If at any time during such 180-day period the closing bid price of the Company’s ordinary shares is at least $1 for a minimum of 10 consecutive business days, Nasdaq will provide the Company written confirmation of compliance. If the Company does not regain compliance during such 180-day period, the Company may be eligible for an additional 180 calendar days, provided that the Company meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for Nasdaq except for Nasdaq Listing Rule 5550(a)(2), and provide a written notice of its intention to cure this deficiency during the second compliance period, by effecting a reverse stock split, if necessary. Announcement • Aug 01
China SXT Pharmaceuticals, Inc. announced delayed 20-F filing On 07/31/2024, China SXT Pharmaceuticals, Inc. announced that they will be unable to file their next 20-F by the deadline required by the SEC. New Risk • Apr 12
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 74% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 33% per year over the past 5 years. Shareholders have been substantially diluted in the past year (74% increase in shares outstanding). Market cap is less than US$10m (US$1.08m market cap). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Revenue is less than US$5m (US$1.7m revenue). New Risk • Feb 16
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (34% average weekly change). Earnings have declined by 35% per year over the past 5 years. Shareholders have been substantially diluted in the past year (75% increase in shares outstanding). Market cap is less than US$10m (US$1.23m market cap). Minor Risks Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Revenue is less than US$5m (US$2.0m revenue). Announcement • Oct 27
China SXT Pharmaceuticals Regains Compliance with Nasdaq’s Minimum Bid Price Rule China SXT Pharmaceuticals, Inc. announced that on October 19, 2023, NASDAQ notified us that it has determined that for the 10 consecutive business days, from October 5, 2023 to October 13, 2023, the closing bid price of the Company’s ordinary shares has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2) and NASDAQ has closed this matter. Announcement • Oct 05
China SXT Pharmaceuticals Announces One-for-Twenty-Five Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Stock Market China SXT Pharmaceuticals, Inc. (the ‘company’) announced that its Board of Directors has set the date of October 5, 2023 to be the effective date for the Company’s one-for-twenty-five reverse stock split of its issued and outstanding ordinary shares. The Company’s ordinary shares will begin trading on the NASDAQ Stock Market on a split-adjusted basis when the market opens on October 5, 2023. The CUSIP number for the Company’s ordinary shares will be changed to G2161P140. The Company’s Board of Directors approved a reverse stock split so as to regain compliance with the minimum bid price requirement of $1.00 per share for continued listing on the NASDAQ Stock Market. In order to maintain the Company’s listing on the NASDAQ Capital Market, the Company’s ordinary shares must have a closing bid price of $1.00 or more for a minimum of ten consecutive trading days by October 30, 2023. There can be no assurance that following the reverse split, the Company’s ordinary shares will remain above $1.00 per share minimum for the requisite period as of October 30, 2023 to regain listing compliance. In the event the Company does not regain compliance with the minimum bid price requirement, its securities may be subject to delisting from the NASDAQ Stock Market which, in turn, will result in significant adverse effect on the value and liquidity of the Company’s securities. Reported Earnings • Aug 01
Full year 2023 earnings released: US$0.89 loss per share (vs US$5.52 loss in FY 2022) Full year 2023 results: US$0.89 loss per share. Net loss: US$5.93m (loss widened 3.5% from FY 2022). Announcement • May 11
China SXT Pharmaceuticals Receives 180-Day Extension from Nasdaq to Meet Minimum Bid Price Rule On May 10, 2023, China SXT Pharmaceuticals, Inc. announced that on May 4, 2023, the company received a written notification from the Nasdaq's Listing Qualifications Department, granting the company another 180 calendar days extension, or until October 30, 2023, to regain compliance with Nasdaq’s minimum bid price requirement. The company can cure this deficiency if the closing bid price of its ordinary shares is $1.00 per share or higher for at least 10 consecutive business days during this second compliance period. The Company intends to regain compliance with the minimum bid price requirement on or before October 30, 2023 and is considering all available options, including a reverse stock split if necessary. During this time, the Company's ordinary shares will continue to be listed and traded on the Nasdaq Capital Market, and this notice will have no effect on the operations of the Company’s business. Reported Earnings • Feb 26
First half 2023 earnings released: US$0.58 loss per share (vs US$3.98 loss in 1H 2022) First half 2023 results: US$0.58 loss per share (improved from US$3.98 loss in 1H 2022). Revenue: US$1.21m (up 18% from 1H 2022). Net loss: US$1.49m (loss narrowed 52% from 1H 2022). Reported Earnings • Jul 19
Full year 2022 earnings released: US$5.52 loss per share (vs US$3.82 loss in FY 2021) Full year 2022 results: US$5.52 loss per share (down from US$3.82 loss in FY 2021). Revenue: US$2.60m (down 46% from FY 2021). Net loss: US$5.74m (loss widened 109% from FY 2021). Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Wenwei Fan was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Jan 19
First half 2022 earnings: Revenues and EPS in line with analyst expectations First half 2022 results: US$0.20 loss per share (down from US$0.096 profit in 1H 2021). Revenue: US$1.03m (down 73% from 1H 2021). Net loss: US$3.09m (down 324% from profit in 1H 2021). Revenue was in line with analyst estimates. Board Change • Nov 02
Less than half of directors are independent There are 4 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. 2 independent directors (3 non-independent directors). Independent Director Junsong Li is the most experienced director on the board, commencing their role in 2019. Independent Director Wenwei Fan was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors. Is New 90 Day High Low • Feb 17
New 90-day high: US$1.28 The company is up 360% from its price of US$0.28 on 18 November 2020. The American market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Personal Products industry, which is up 15% over the same period. Reported Earnings • Jan 31
First half 2021 earnings released: EPS US$0.026 (vs US$0.10 loss in 1H 2020) The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: US$3.86m (up 20% from 1H 2020). Net income: US$1.38m (up US$3.73m from 1H 2020). Profit margin: 36% (up from net loss in 1H 2020). Is New 90 Day High Low • Jan 30
New 90-day high: US$0.73 The company is up 157% from its price of US$0.28 on 30 October 2020. The American market is up 17% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Personal Products industry, which is up 17% over the same period. Is New 90 Day High Low • Jan 05
New 90-day high: US$0.39 The company is up 56% from its price of US$0.25 on 06 October 2020. The American market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Personal Products industry, which is up 22% over the same period. Is New 90 Day High Low • Dec 02
New 90-day high: US$0.34 The company is up 28% from its price of US$0.27 on 02 September 2020. The American market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Personal Products industry, which is up 14% over the same period. Is New 90 Day High Low • Sep 22
New 90-day low: US$0.23 The company is down 52% from its price of US$0.48 on 24 June 2020. The American market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 8.0% over the same period. 
